Journal article icon

Journal article

A phase 2a randomized study to evaluate the safety and immunogenicity of the 1790GAHB GMMA vaccine against Shigella sonnei administered intramuscularly to adults from a shigellosis-endemic country

Abstract:

Shigellosis is a mild-to-severe diarrheal infection caused by the genus Shigella and responsible for significant morbidity and mortality worldwide. We evaluated the safety and immunogenicity of an investigational Shigella sonnei vaccine (1790GAHB) based on Generalized Modules for Membrane Antigens (GMMA) in Kenya, a Shigella-endemic country. This phase 2a, observer-blind, controlled study (NCT02676895) enrolled and randomized 74 healthy adults aged 18–45 years, of whom 72 were vaccinated. Par...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.3389/fimmu.2017.01884

Authors


Obiero, CW More by this author
Ndiaye, AG More by this author
Scirè, AS More by this author
Kaunyangi, BM More by this author
Marchetti, E More by this author
Expand authors...
Publisher:
Frontiers Media Publisher's website
Journal:
Frontiers in Immunology Journal website
Volume:
8
Pages:
Article: 1884
Publication date:
2017-12-22
Acceptance date:
2017-12-07
DOI:
ISSN:
1664-3224
Pubs id:
pubs:812229
URN:
uri:ae435ad9-621c-48d9-972d-efd991e63819
UUID:
uuid:ae435ad9-621c-48d9-972d-efd991e63819
Local pid:
pubs:812229

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP